MannKind Corp. (MNKD)
4.09
+0.02
(+0.49%)
USD |
NASDAQ |
Nov 18, 14:16
MannKind Net Income (Quarterly) : -23.22M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -23.22M |
| June 30, 2026 | -19.03M |
| March 31, 2026 | -16.62M |
| December 31, 2025 | -15.95M |
| September 30, 2025 | 7.985M |
| June 30, 2025 | 0.668M |
| March 31, 2025 | 13.16M |
| December 31, 2024 | 7.422M |
| September 30, 2024 | 11.55M |
| June 30, 2024 | -2.014M |
| March 31, 2024 | 10.63M |
| December 31, 2023 | 1.401M |
| September 30, 2023 | 1.721M |
| June 30, 2023 | -5.265M |
| March 31, 2023 | -9.795M |
| December 31, 2022 | -17.95M |
| September 30, 2022 | -14.43M |
| June 30, 2022 | -29.02M |
| March 31, 2022 | -26.00M |
| December 31, 2021 | -28.06M |
| September 30, 2021 | -4.426M |
| June 30, 2021 | -35.52M |
| March 31, 2021 | -12.92M |
| December 31, 2020 | -26.41M |
| September 30, 2020 | -11.26M |
| Date | Value |
|---|---|
| June 30, 2020 | -10.25M |
| March 31, 2020 | -9.322M |
| December 31, 2019 | -14.26M |
| September 30, 2019 | -10.37M |
| June 30, 2019 | -12.39M |
| March 31, 2019 | -14.88M |
| December 31, 2018 | -9.747M |
| September 30, 2018 | -24.17M |
| June 30, 2018 | -22.68M |
| March 31, 2018 | -30.38M |
| December 31, 2017 | -32.78M |
| September 30, 2017 | -32.89M |
| June 30, 2017 | -35.34M |
| March 31, 2017 | -16.32M |
| December 31, 2016 | 53.98M |
| September 30, 2016 | 126.52M |
| June 30, 2016 | -29.96M |
| March 31, 2016 | -24.87M |
| December 31, 2015 | -277.02M |
| September 30, 2015 | -31.86M |
| June 30, 2015 | -28.91M |
| March 31, 2015 | -30.66M |
| December 31, 2014 | -36.44M |
| September 30, 2014 | -36.52M |
| June 30, 2014 | -73.36M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| United Therapeutics Corp. | 258.60M |
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Savara, Inc. | -42.99M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 101.87M |
| Total Expenses (Quarterly) | 125.09M |
| EPS Diluted (Quarterly) | -0.0725 |
| Enterprise Value | 1.648B |
| Gross Profit Margin (Quarterly) | 71.85% |
| Profit Margin (Quarterly) | -22.80% |
| Earnings Yield | -5.87% |
| Normalized Earnings Yield | -5.049 |